A Phase II Clinical Trial to Assess the Effect of HC-SVT-1001 (Autologous Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) and HC-SVT-1002 (Allogeneic Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones
Phase of Trial: Phase I/II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs HC SVT-1001 (Primary)
- Indications Pseudoarthrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Bonecure
- Sponsors SALVAT
- 02 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2021.
- 02 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 13 Aug 2018 Planned number of patients changed from 10 to 12.